CClinicalTrials.gg
Enrolling by invitationNCT06674122Updated Nov 6, 2024

Efficacy of Higher Dose Enteral Vitamin D Supplementation in Preterm 28 - 34 Weeks of Gestational Age

An interventional study of Enteral vitamin D supplementation of 800 IU/day and Enteral vitamin D supplementation of 400 IU/day in Vitamin D Supplementation, sponsored by Indonesia University. Enrolling by invitation at 1 site in Indonesia. Open to participants aged 28 Weeks to 34 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by Indonesia University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 7 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 3 months after the study started (first participant enrolled Jul 2024, registered Nov 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
28 Weeks to 34 Weeks
Sex
All
01

Study summary

The goal of this clinical trial is to learn about the effective dosage of enteral vitamin D supplementation in preterm infants with gestational age fom 28 to 34 weeks. The main questions it aims to answer is:

  • Does higher dose of enteral vitamin D supplementation (800IU/day) increase vitamin D level better than standard recommended dose (400IU/day) to achieve sufficient level of vitamin D?

Participants will:

  • Take the enteral vitamin D supplementation every fay for 28 days
  • Have their blood level of vitamin D examined before and after supplementation for 28 days
Read the detailed description

The study conducted in 2 hospitals in Jakarta region, RSCM and RSUD Koja. Preterm with 28 to 34 weeks of gestational age and fulfill the inclusion criteria will be enrolled in the study after parents signed the informed consent.

Blood sample will be collected to get the baseline of vitamin D serum. The study subject will be given enteral vitamin D supplementation for 28 days (4 weeks). The dosage of vitamin D is randomized with block randomized in sealed envelope.

Subjects then will be followed up to 28 days of supplementation. After 28 days of supplementation, the subjects' blood will be collected to get the vitamin D serum level. Data taken will be analyzed using IBM Statistical Product and Service Solutions (SPSS).

02

Conditions studied

  • Vitamin D Supplementation

Browse trials for

Keywords

  • vitamin D supplementation in preterm
03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's planned enrollment of 54 is below the median of 84 across 1,689 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Indonesia University is the lead sponsor of 448 studies on the registry; 56 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 34 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • neonates with gestational age 28-34 weeks
  • tolerated enteral feedings more than 30ml/kg

Exclusion criteria

Exclusion Criteria:

  • infants with major congenital anomaly
  • infants with gastrointestinal obstruction
  • infants with congenital renal failure
  • infants with cholestassis
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
54 participants (estimated)

Study arms

  • Active comparator
    400 IU

    Participants will receive enteral vitamin D supplementation of 400 IU/day for 28 days

    Dietary Supplement: Enteral vitamin D supplementation of 400 IU/day

  • Experimental
    800 IU

    Participants will receive enteral vitamin D supplementation of 800 IU/day for 28 days

    Dietary Supplement: Enteral vitamin D supplementation of 800 IU/day

Interventions

  • Dietary supplementEnteral vitamin D supplementation of 800 IU/day

    Higher dose of enteral vitamin D supplementations (800 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation

  • Dietary supplementEnteral vitamin D supplementation of 400 IU/day

    Standard recommended dose of enteral vitamin D supplementations (400 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation

06

What researchers measure

Primary outcomes

  1. 25(OH)D level

    serum level of 25(OH)D

    Time frame: From enrollment to the end of treatment at 4 weeks

07

Study locations

1 site
  • Cipto Mangunkusumo Hospital
    Jakarta, Central Jakarta 10430, Indonesia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06674122
Lead sponsor
Indonesia University
Responsible party
Rosalina Dewi Roeslani (Head of Neonatology Division, Principal Investigator, Indonesia University) — Principal investigator
First posted
Nov 5, 2024
Start date
Jul 17, 2024
Primary completion
Feb 28, 2025 (estimated)
Completion
Mar 10, 2025 (estimated)
Last update
Nov 6, 2024

Study contacts

Rosalina D Roeslani, dr, SpA(K)
principal investigator · FKUI RSCM

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion